GlassScriptPhysician profile
Melinda Collins
NPI 1407146400
$6,059.16
in general payments reported to CMS, 2019-2025
31 companies · $1,023 in 2025
The $1,023 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,100 · 2020: $655 · 2021: $521 · 2022: $701 · 2023: $288 · 2024: $770 · 2025: $1,023.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,065 · Education: $16.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,064.81 |
| Education | $16.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,187.19 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Abbvie INC. | $738.74 | 2019-2025 | Rinvoq, Humira |
| Pfizer INC. | $607.22 | 2019-2024 | |
| Genzyme Corporation | $472.97 | 2019-2025 | |
| Janssen Biotech, INC. | $403.08 | 2019-2025 | Tremfya, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $395.22 | 2019-2025 | |
| Lilly USA, LLC | $324.21 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $302.02 | 2019-2025 | Orencia |
| Genentech USA, INC. | $257.96 | 2019-2024 | Actemra |
| Ucb, INC. | $234.94 | 2019-2025 | Bimzelx |
| Astrazeneca Pharmaceuticals LP | $138.90 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $115.18 | 2020-2025 | Acthar |
| Aurinia Pharma U.S., INC. | $103.79 | 2021-2024 | Lupkynis |
| Radius Health, INC. | $101.18 | 2019-2025 | Tymlos |
| Glaxosmithkline, LLC. | $93.62 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.27 | 2022-2025 | Sovuna, Purified Cortrophin Gel |
| Sanofi-Aventis U.S. LLC | $78.46 | 2019 | |
| Mallinckrodt Enterprises LLC | $76.17 | 2019 | |
| Horizon Therapeutics Plc | $58.76 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.05 | 2019-2025 | Ofev |
| Merck Sharp & Dohme LLC | $43.36 | 2019 | |
| Sobi, INC | $40.39 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $28.32 | 2022-2023 | Arcalyst |
| Medexus Pharma, INC. | $24.73 | 2019-2020 | |
| Kiniksa Pharmaceuticals International, Plc | $16.70 | 2024 | Arcalyst |
| Celltrion USA INC. | $16.67 | 2023 | Yuflyma |
| Medtronic, INC. | $16.51 | 2024 | Minimed 780g |
| Hikma Pharmaceuticals USA | $14.63 | 2020 | |
| Novo Nordisk INC | $14.49 | 2020 | |
| Alexion Pharmaceuticals, INC. | $13.69 | 2022 | |
| Avion Pharmaceuticals | $11.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.